Depsipeptide and uses thereof
The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.
1. A method of treating a bacterial infection in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a compound of Formula (II), or a tautomer or a pharmaceutically-acceptable salt thereof, and a pharmaceutically acceptable carrier; wherein the compound of Formula (II) is:
2. The method of claim 1 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a sugar, a starch, a cellulose, an oil, a glycol, an alcohol, an ester, and a fatty acid ester of sorbitan.
3. The method of claim 1 , wherein the pharmaceutically acceptable carrier is a sugar.
4. The method of claim 3 , wherein the sugar is selected from the group consisting of lactose, glucose, and sucrose.
5. The method of claim 1 , wherein the bacterial infection is caused by a Gram-positive bacterium.
6. The method of claim 5 , wherein the Gram-positive bacterium is selected from the group consisting of Streptococcus, Staphylococcus, Enterococcus, Corynebacteria, Listeria, Bacillus, Erysipelothrix, Mycobacterium, Clostridium , and Actinomycetales.
7. The method of claim 5 , wherein the Gram-positive bacterium is selected from the group consisting of methicillin-susceptible and methicillin-resistant staphylococci (including Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus , and coagulase-negative staphylococci), glycopeptide intermediate-susceptible Staphylococcus aureus (GISA), penicillin-susceptible and penicillin-resistant streptococci (including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus avium, Streptococcus bovis, Streptococcus lactis, Streptococcus sangius, Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus and Streptococci Group C, Streptococci Group G and Viridans streptococci ), enterococci (including vancomycin-susceptible and vancomycin-resistant strains such as Enterococcus faecalis and Enterococcus faecium ), Clostridium difficile, Clostridium clostridiiforme, Clostridium innocuum, Clostridium perfringens, Clostridium tetani, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium kansaii, Mycobacterium gordonae, Mycobacteria sporozoites, Listeria monocytogenes, Bacillus subtilis, Bacillus anthracis, Corynebacterium diphtherias, Corynebacterium jeikeium, Corynebacterium sporozoites, Erysipelothrix rhusiopathiae , and Actinomyces israelli.
8. The method of claim 7 , wherein the bacterial infection is caused by Bacillus anthracis.
9. The method of claim 1 , wherein the bacterial infection is caused by a Gram-negative bacterium.
10. The method of claim 9 , wherein the Gram-negative bacterium is selected from the group consisting of Helicobacter pylori, Legionella pneumophilia, Neisseria gonorrhoeae, Neisseria meningitidis , pathogenic Campylobacter sporozoites, Haemophilus influenzae, Pseudomonas aeruginosa, Enterobacter aerogenes, Enterobacter cloacae, Klebsiella pneumoniae, Klebsiella oxytoca, Pasteurella multocida, Bacteroides sporozoites, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus Fusobacterium nucleatum, Streptobacillus moniliformis, Leptospira, Escherichia coli, Salmonella enterica, Salmonella salamae, Salmonella arizonae, Salmonella diarizonae, Salmonella houtenae, Salmonella bongori, Salmonella indica, Salmonella Enteritidis, Salmonella typhi , and Citrobacter freundii.
11. A method of treating a bacterial infection in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a compound of Formula (III), or a tautomer or pharmaceutically-acceptable salt thereof, wherein the compound of Formula (III) is:
wherein each R 1 -R 6 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, C(═O)R a and S(═O) 2 R b ; each R a is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, or aryl; and each R b is independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, or aryl.
12. The method of claim 11 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a sugar, a starch, a cellulose, an oil, a glycol, an alcohol, an ester, and a fatty acid ester of sorbitan.
13. The method of claim 11 , wherein the pharmaceutically acceptable carrier is a sugar.
14. The method of claim 13 , wherein the sugar is selected from the group consisting of lactose, glucose, and sucrose.
15. The method of claim 11 , wherein the bacterial infection is caused by a Gram-positive bacterium.
16. The method of claim 15 , wherein the Gram-positive bacterium is selected from the group consisting of Streptococcus, Staphylococcus, Enterococcus, Corynebacteria, Listeria, Bacillus, Erysipelothrix, Mycobacterium, Clostridium , and Actinomycetales.
17. The method of claim 15 , wherein the Gram-positive bacterium is selected from the group consisting of methicillin-susceptible and methicillin-resistant staphylococci (including Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus , and coagulase-negative staphylococci), glycopeptide intermediate-susceptible Staphylococcus aureus (GISA), penicillin-susceptible and penicillin-resistant streptococci (including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus avium, Streptococcus bovis, Streptococcus lactis, Streptococcus sangius, Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus and Streptococci Group C, Streptococci Group G and Viridans streptococci ), enterococci (including vancomycin-susceptible and vancomycin-resistant strains such as Enterococcus faecalis and Enterococcus faecium ), Clostridium difficile, Clostridium clostridiiforme, Clostridium innocuum, Clostridium perfringens, Clostridium tetani, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium kansaii, Mycobacterium gordonae, Mycobacteria sporozoites, Listeria monocytogenes, Bacillus subtilis, Bacillus anthracis, Corynebacterium diphtherias, Corynebacterium jeikeium, Corynebacterium sporozoites, Erysipelothrix rhusiopathiae , and Actinomyces israelli.
18. The method of claim 17 , wherein the bacterial infection is caused by Bacillus anthracis.
19. The method of claim 11 , wherein the bacterial infection is caused by a Gram-negative bacterium.
20. The method of claim 19 , wherein the Gram-negative bacterium is selected from the group consisting of Helicobacter pylori, Legionella pneumophilia, Neisseria gonorrhoeae, Neisseria meningitidis , pathogenic Campylobacter sporozoites, Haemophilus influenzae, Pseudomonas aeruginosa, Enterobacter aerogenes, Enterobacter cloacae, Klebsiella pneumoniae, Klebsiella oxytoca, Pasteurella multocida, Bacteroides sporozoites, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus Fusobacterium nucleatum, Streptobacillus moniliformis, Leptospira, Escherichia coli, Salmonella enterica, Salmonella salamae, Salmonella arizonae, Salmonella diarizonae, Salmonella houtenae, Salmonella bongori, Salmonella indica, Salmonella Enteritidis, Salmonella typhi , and Citrobacter freundii.